Marbocare flavour 5 mg tablets for dogs and cats

Main information

  • Trade name:
  • Marbocare flavour 5 mg tablets for dogs and cats
  • Pharmaceutical form:
  • Tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Marbocare flavour 5 mg tablets for dogs and cats
    Portugal
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Fluoroquinolones
  • Therapeutic area:
  • Cats Non Food, Dogs Non Food

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0470/001
  • Authorization date:
  • 26-06-2013
  • EU code:
  • UK/V/0470/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage, interactions, side effects

Issued:September2013

AN:00538/2012

Page1of6

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Marbocareflavour5mgtabletsfordogsandcats(UKandIE)

MarbocareF5mgtabletsfordogsandcats(FR)

Odimar5mgtabletsfordogsandcats(BE,LU,NL)

MarbofloxacinWDT5mgflavouredtabletsforcatsanddogs(AT,DE)

MarbofloxacinoEmdoka5mgtabletsforcatsanddogs(ES)

MarbofloxacinaEmdoka5mgtabletsforcatsanddogs(PT)

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachtabletcontains:

Activesubstance:Marbofloxacin5.0mg

Excipients:

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Tablet

Beigebrownspottedroundtabletswithascorelineononeside.

4. CLINICALPARTICULARS

4.1Targetspecies

DogsandCats

4.2Indicationsforuse,specifyingthetargetspecies

Marbofloxacinisindicatedinthetreatmentofthefollowinginfectionscausedby

susceptiblestrainsoforganisms(seesection5.1);

Dogs

Skinandsofttissueinfections(skinfoldpyoderma,impetigo,folliculitis,

furunculosis,cellulitis)

Urinarytractinfections(UTI)associatedornotwithprostatitisorepididymitis

Respiratorytractinfections

Issued:September2013

AN:00538/2012

Page2of6

Cats

Skinandsofttissueinfections(wounds,abscesses,phlegmons)

Upperrespiratorytractinfections

4.3Contraindications

Donotuseindogsagedlessthan12months,orlessthan18monthsforexceptionally

largebreedsofdogs,suchasGreatDanes,Briard,Bernese,BouvierandMastiffs,with

alongergrowthperiod.

Notrecommendedforuseincatsagedlessthan16weeks.

Donotuseinanimalswithknownhypersensitivitytomarbofloxacinorother

(fluoro)quinolonesortoanyoftheexcipients.

Donotuseincaseofconfirmedorsuspectedresistancetofluoroquinolones(cross

resistance).

4.4Specialwarningsforeachtargetspecies

AlowurinarypHcouldhaveaninhibitoryeffectontheactivityofmarbofloxacin.

4.5Specialprecautionsforuse

Specialprecautionsforuseinanimals

Thefluoroquinoloneshavebeenshowntoinduceerosionofarticularcartilageinjuvenile

dogsandcareshouldbetakentodoseaccuratelyespeciallyinyounganimals.

However,atthetherapeuticrecommendeddosage,noseveresideeffectsaretobe

expectedindogsandcats.

Somefluoroquinolonesathighdosesmayhaveanepileptogenicpotential.Cautious

useisrecommendedindogsandcatsdiagnosedassufferingfromepilepsy.

Fluoroquinolonesshouldbereservedforthetreatmentofclinicalconditionswhichhave

respondedpoorly,orareexpectedtorespondpoorlytootherclassesofantimicrobials.

Wheneverpossible,useoffluoroquinolonesshouldbebasedonsusceptibilitytesting.

UseoftheproductdeviatingfromtheinstructionsgivenintheSPCmayincreasethe

prevalenceofbacteriaresistanttothefluoroquinolonesandmaydecrease

effectivenessoftreatmentwithotherquinolonesduetothepotentialforcross-

resistance.

Issued:September2013

AN:00538/2012

Page3of6

Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Peoplewithknownhypersensitivityto(fluoro)quinolonesshouldavoidusingthisproduct.

Incaseofaccidentalingestionseekmedicalattentionandshowproductlabeland/or

packageleaflettothedoctor.Washhandsafteruse.

4.6Adversereactions(frequencyandseriousness)

Mildsideeffectssuchasvomiting,softeningoffaeces,modificationofthirstortransient

increaseinactivitymayoccasionallyoccur.Thesesignsceasespontaneouslyafter

treatmentanddonotnecessitatecessationoftreatment.

4.7Useduringpregnancy,lactationorlay

Studiesinlaboratoryanimals(rats,rabbits)showednoteratogenicity,embryotoxicity

andmaternotoxicitywithmarbofloxacinattherapeuticdoses.

Thesafetyofmarbofloxacinhasnotbeenassessedinpregnantandlactatingcatsand

dogs.Useonlyaccordinglytothebenefit/riskassessmentbytheresponsible

veterinarianinpregnantandlactatinganimals.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Fluoroquinolonesareknowntointeractwithorallyadministeredcations(Aluminium,

Calcium,Magnesium,Iron).Insuchcases,thebioavailabilitymaybereduced.

Whenadministeredtogetherwiththeophylline,thehalf-lifeandthustheplasma

concentrationoftheophyllineincrease.Hence,incaseofconcurrentadministrationthe

doseoftheophyllineshouldbereduced.

4.9Amountstobeadministeredandadministrationroute

Fororaladministration.

Therecommendeddoserateis2mg/kg/dayinasingledailyadministration(seetable

below).

BodyWeight Tablets

1.3 –2.5kg 1

2.6 –5.0kg 2

Issued:September2013

AN:00538/2012

Page4of6

Toensureacorrectdosagebodyweightshouldbedeterminedasaccuratelyas

possibletoavoidunderdosing.

DOGS:

 Inskinandsofttissueinfections,treatmentdurationisatleast5days.Depending

onthecourseofthedisease,itmaybeextendedupto40days.

 Inurinarytractinfections,treatmentdurationisatleast10days.Dependingonthe

courseofthedisease,itmaybeextendedupto28days.

Inrespiratoryinfections,treatmentdurationisatleast7daysanddependingonthe

courseofthedisease,itmaybeextendedupto21days.

CATS:

 Forskinandsofttissueinfections(wounds,abscesses,phlegmons)treatment

durationis3to5days.

 Forupperrespiratoryinfectionstreatmentdurationis5days.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Overdosagemaycauseacutesignsintheformofneurologicaldisorders,whichshould

betreatedsymptomatically.

4.11Withdrawalperiod(s)

Notapplicable.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Antibacterialsforsystemicuse;

Fluoroquinolones;Marbofloxacin.

ATCvetcode:QJ01MA93

5.1Pharmacodynamicproperties

Marbofloxacinisasynthetic,bactericidalantimicrobial,belongingtothefluoroquinolone

groupwhichactsbyinhibitionofDNAgyrase.Itiseffectiveagainstawiderangeof

Grampositivebacteria(inparticularStaphylococci,Streptococci)andGramnegative

bacteria(Escherichiacoli,Salmonellatyphimurium,Citrobacterfreundii,Enterobacter

cloacae,Serratiamarcescens,Morganellamorganii,Proteusspp,Klebsiellaspp,

Shigellaspp,Pasteurellaspp,Haemophilusspp,Moraxellaspp,Pseudomonasspp,

Brucellacanis)aswellasMycoplasmaspp.

BacterialstrainswithaMIC≤1µg/mlaresusceptible,strainswithaMICof2µg/mlare

intermediatelysusceptibleandstrainswithaMIC≥4µg/mlareresistantto

marbofloxacin(CLSI,2004).MIC

90 valuesofmarbofloxacinforstrainsof

Staphylococcus(pseudo)intermedius,EscherichiacoliandPasteurellamultocida

Issued:September2013

AN:00538/2012

Page5of6

isolatedfromdiseasedcatsanddogsinGermanywere0.5µg/ml,0.5µg/mland0.06

µg/ml,respectively.

Resistancetofluoroquinolonesoccursmostlybychromosomalmutationwiththree

mechanisms:decreaseofthebacterialwallpermeability,expressionofeffluxpumpor

mutationofenzymesresponsibleformoleculebinding.

Marbofloxacinisnotactiveagainstanaerobes,yeastsorfungi.

5.2Pharmacokineticparticulars

Afteroraladministrationindogsandcatsattherecommendeddoseof2mg/kg,

marbofloxacinisreadilyabsorbedandreachesmaximalplasmaconcentrationsof1.5

µg/mlwithin2hours

Itsbioavailabilityiscloseto100%.

Itisweaklyboundtoplasmaproteins(lessthan10%),extensivelydistributedandin

mosttissues(liver,kidney,skin,lung,bladder,digestivetract)itachieveshigher

concentrationsthaninplasma.Marbofloxaciniseliminatedslowly(t½ß=14hindogs

and10hincats)predominantlyintheactiveforminurine(2/3)andfaeces(1/3).

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Lactosemonohydrate

Povidone(K90)

Silica,colloidalhydrated

Crospovidone(TypeA)

CastorOil,Hydrogenated

Dessicatedporkliverpowder

Driedyeast

Magnesiumstearate

6.2Incompatibilities

Notapplicable.

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale;3years.

6.4.Specialprecautionsforstorage

Thisveterinarymedicinalproductdoesnotrequireanyspecialstorageconditions.

Issued:September2013

AN:00538/2012

Page6of6

6.5Natureandcompositionofimmediatepackaging

TheproductispackagedinAluminium-PVC/aluminium/polyamideblister

Boxcontaining1blisterof10tablets(10tablets)

Boxcontaining2blistersof10tablets(20tablets)

Boxcontaining10blistersof10tablets(100tablets)

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuchveterinary

medicinalproductsshouldbedisposedofinaccordancewithlocalrequirements.

7. MARKETINGAUTHORISATIONHOLDER

EmdokaBvba

JohnLijsenstraat16

B-2321Hoogstraten

Belgium

8. MARKETINGAUTHORISATIONNUMBER

Vm34534/4003

9. DATEOFFIRSTAUTHORISATION

04September2013

10.DATEOFREVISIONOFTHETEXT

September2013

PROHIBITIONOFSALE,SUPPLYAND/ORUSE

Notapplicable.

Approved:04/09/2013